Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial

NCT04417699 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT04417699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04417699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial
Lead sponsor
Providence Health & Services
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2022
Completion date
February 21, 2024
Enrollment
13 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer